April 16 (Reuters) - Incyte Corp INCY.O :
* LILLY AND INCYTE ANNOUNCE RESULTS FROM THE PHASE 3 COV-BARRIER STUDY OF BARICITINIB IN HOSPITALIZED COVID-19 PATIENTS
* INCYTE CORP - TRIAL DID NOT MEET STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT
* INCYTE CORP - BARICITINIB-TREATED PATIENTS WERE 2.7 PER CENT LESS LIKELY THAN THOSE RECEIVING STANDARD OF CARE TO PROGRESS TO VENTILATION OR DEATH
* INCYTE CORP - FREQUENCY OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS WERE GENERALLY SIMILAR IN BARICITINIB AND PLACEBO GROUPS
* INCYTE CORP - NO NEW SAFETY SIGNALS POTENTIALLY RELATED TO USE OF BARICITINIB WERE IDENTIFIED